Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.
Vilorio-Marqués L, Castañón Fernández C, Mora E, Gutiérrez L, Rey Bua B, Jiménez Lorenzo MJ, Díaz Beya M, Vara Pampliega M, Molero A, Sánchez-García J, Calabuig M, Cedena MT, Chen-Liang T, Díaz Santa JA, Padilla I, Hernández F, Díez R, Asensi P, Xicoy B, Sanz G, Valcárcel D, Diez-Campelo M, Bernal T. Vilorio-Marqués L, et al. Among authors: cedena mt. Ther Adv Hematol. 2022 Sep 29;13:20406207221127547. doi: 10.1177/20406207221127547. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36199837 Free PMC article.
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Triguero A, Xicoy B, Zamora L, Jiménez MJ, García O, Calabuig M, Díaz-Beyá M, Arzuaga J, Ramos F, Medina A, Bernal T, Talarn C, Coll R, Collado R, Chen TH, Borrás J, Brunet S, Marchante I, Marco V, López-Cadenas F, Calbacho M, Simiele A, Cortés M, Cedena MT, Pedreño M, Aguilar C, Pedró C, Fernández M, Stoica C, Ribera JM, Sanz G. Triguero A, et al. Among authors: cedena mt. Leuk Res. 2022 May;116:106836. doi: 10.1016/j.leukres.2022.106836. Epub 2022 Mar 26. Leuk Res. 2022. PMID: 35405632
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Diez-Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, Andreu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy B, Ramos F, Bargay J, Gonzalez B, Brunet S, Muñoz JA, Gomez V, Bailén A, Sanchez J, Merchán B, del Cañizo C, Vallespí T; Grupo Español de Síndromes Mielodisplásicos (GESMD). Valcárcel D, et al. Among authors: cedena mt. Lancet Haematol. 2015 Jun;2(6):e260-6. doi: 10.1016/S2352-3026(15)00067-8. Epub 2015 May 20. Lancet Haematol. 2015. PMID: 26688236
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Palomo L, Ibáñez M, Abáigar M, Vázquez I, Álvarez S, Cabezón M, Tazón-Vega B, Rapado I, Fuster-Tormo F, Cervera J, Benito R, Larrayoz MJ, Cigudosa JC, Zamora L, Valcárcel D, Cedena MT, Acha P, Hernández-Sánchez JM, Fernández-Mercado M, Sanz G, Hernández-Rivas JM, Calasanz MJ, Solé F, Such E; Spanish Group of MDS (GESMD). Palomo L, et al. Among authors: cedena mt. Br J Haematol. 2020 Mar;188(5):605-622. doi: 10.1111/bjh.16175. Epub 2019 Oct 16. Br J Haematol. 2020. PMID: 31621063 Free PMC article.
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J. Cedena MT, et al. Oncotarget. 2017 Oct 27;8(63):106948-106961. doi: 10.18632/oncotarget.22157. eCollection 2017 Dec 5. Oncotarget. 2017. PMID: 29291002 Free PMC article.
Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J. Cedena MT, et al. Oncotarget. 2018 Jul 20;9(56):30936. doi: 10.18632/oncotarget.25856. eCollection 2018 Jul 20. Oncotarget. 2018. PMID: 30112119 Free PMC article.
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Kuendgen A, et al. Among authors: cedena mt. Leukemia. 2021 Mar;35(3):835-849. doi: 10.1038/s41375-020-0917-7. Epub 2020 Jun 29. Leukemia. 2021. PMID: 32595214 Free PMC article.
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Gil-Alós D, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. Jiménez-Ubieto A, et al. Among authors: cedena mt. Front Immunol. 2024 Jan 10;14:1349296. doi: 10.3389/fimmu.2023.1349296. eCollection 2023. Front Immunol. 2024. PMID: 38268917 Free PMC article.
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Guerrero C, Puig N, Cedena MT, Calasanz MJ, Gutierrez NC, Fernandez M, Oriol A, Ríos-Tamayo R, Hernandez MT, Martínez-Martínez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Gonzalez Perez MS, Orfao A, Mateos MV, Martinez-Lopez J, Rosiñol L, Bladé J, Lahuerta JJ, San-Miguel JF, Paiva B. Guerrero C, et al. Among authors: cedena mt. Blood. 2024 Feb 15;143(7):597-603. doi: 10.1182/blood.2023022083. Blood. 2024. PMID: 38048552
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S, Rosiñol L, Puig N, Pico-Picos MA, Medina-González L, Martínez-López J, Paiva B, Cedena MT, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, González E, Casado LF, Martí JM, Encinas C, De Arriba F, Palomera L, Sampol A, González-Montes Y, Motlló C, De La Cruz J, Alonso R, Mateos MV, Bladé J, Lahuerta JJ, San-Miguel J, Hernández MT. Lakhwani S, et al. Among authors: cedena mt. Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.284154. Online ahead of print. Haematologica. 2023. PMID: 38031761 Free article.
60 results